Combination therapy highlights increased apoptosis and decreased cell viability in CT26 cells, suggesting synergistic effects of oncolytic reovirus and ammonium metavanadate.
BackgroundCombination therapy for cancer using oncolytic viruses and anticancer drugs/agents has better therapeutic effects through direct destructive effects on cancer defence. Direct destructive effects of both factors and triggering an enhanced immune response can augment the anticancer effect in a synergistic manner. e. This study aimed to evaluate the efficacy of ammonium metavanadate (NH4VO3) as an anticancer agent combined with oncolytic reovirus serotype 3, Dearing strain (ReoT3D), in the induction of cytotoxic effect in a murine colorectal cancer cell line (CT26 cells).MethodsThe impact of NH4VO3, ReoT3D, and their synergistic effect on the viability of CT26 cells was assessed using the MTT assay. The rate of apoptosis induction and cell cycle arrest by NH4VO3 and ReoT3D was evaluated by flow cytometry and real-time PCR.ResultsThe results showed that cell viability decreased with increasing NH4VO3 dosage, viral titer, and treatment time. Regarding the induction of apoptosis by oncolytic reovirus and NH4VO3, apoptosis was increased because of the synergism of NH4VO3 and ReoT3D, and the cell cycle was arrested with the combined treatment. Caspase 3, 8, and p53 gene expression increased and bcl-2 gene expression decreased.ConclusionCombination therapy using oncolytic ReoT3D and NH4VO3 increases apoptosis in cancer cells and can be used as a promising platform for scientific studies and research in cancer treatment.
No takes yet. Share an insight, caveat, or question.
Asiyabi et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: